Document 1115
 DOCN  M94A1115
 TI    The effects of AZT on survival: a review of published randomized
       evidence.
 DT    9412
 AU    Smith R; Abrams D; Mitchell T; Meier P; Peto R
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):205 (abstract no. PB0835). Unique
       Identifier : AIDSLINE ICA10/94371460
 AB    TABULAR DATA, SEE ABSTRACT VOLUME. The failure of all but the first
       placebo controlled AZT trial to detect a statistically significant
       survival benefit is often incorrectly viewed as evidence that there is
       no survival benefit associated with early intervention with AZT. A
       review of the totality of the currently available published evidence
       does not exclude the possibility of moderate benefit, or, alternatively
       of moderate harm from early AZT. In fact, even the Concorde trial result
       is compatible with a moderate survival difference between treatment and
       control. In order to reliably determine whether a moderate benefit on
       the order of 10-40% might be associated with earlier intervention with
       AZT, trials will have to be enlarged an order of magnitude.
 DE    Acquired Immunodeficiency Syndrome/DRUG THERAPY/*MORTALITY  Human
       Randomized Controlled Trials  Survival Rate  Zidovudine/*THERAPEUTIC USE
       MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).